Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Hale, Matthew B ^a   Krutzik, Peter O ^a   Samra, Shamsher S ^a   Crane, Janelle M ^a   Nolan, Garry P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD11B ANTIGEN; CD45 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 6; JANUS KINASE 1; STAT PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; CYTOKINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INHIBITION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; OSCILLATION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MURINAE;

ANIMALS; BLOTTING, WESTERN; CYTOKINES; DISEASE PROGRESSION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 69449090795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006756     Document Type: Article

References (51)

1. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, et al. (1994) Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 179: 305-310.
2. Viallard JF, Pellegrin JL, Ranchin V, Schaeverbeke T, Dehais J, et al. (1999) Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 115: 189-195.
3. Cross JT, Benton HP (1999) The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus. Inflamm Res 48: 255-261.
4. Csiszar A, Nagy G, Gergely P, Pozsonyi T, Pocsik E (2000) Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 122: 464-470.
5. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, et al. (2000) Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43: 1790-1800.
6. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J (2001) Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 294: 1540-1543.
7. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610-2615.
8. Baechler EC, Gregersen PK, Behrens TW (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 16: 801-807.
9. Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, et al. (2006) Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun 7: 156-168.
10. Leonard WJ, O'Shea JJ (1998) Jaks and STATs: biological implications. Annu Rev Immunol 16: 293-322.
11. Perez OD, Nolan GP (2002) Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat Biotechnol 20: 155-162.
12. Krutzik PO, Nolan GP (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70.
13. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228.
14. Krutzik PO, Hale MB, Nolan GP (2005) Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J Immunol 175: 2366-2373.
15. Sachs K, Perez O, Pe'er D, Lauffenburger DA, Nolan GP (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308: 523-529.
16. Braun D, Geraldes P, Demengeot J (2003) Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice. J Autoimmun 20: 15-25.
17. Balomenos D, Rumold R, Theofilopoulos AN (1998) Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 101: 364-371.
18. Santiago-Raber ML, Baccala R, Haraldsson KM, Choubey D, Stewart TA, et al. (2003) Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 197: 777-788.
19. Lawson BR, Prud'homme GJ, Chang Y, Gardner HA, Kuan J, et al. (2000) Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest 106: 207-215.
20. Chaussabel D, Allman W, Mejias A, Chung W, Bennett L, et al. (2005) Analysis of significance patterns identifies ubiquitous and disease-specific gene-expression signatures in patient peripheral blood leukocytes. Ann N Y Acad Sci 1062: 146-154.
21. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-723.
22. Pascual V, Allantaz F, Patel P, Palucka AK, Chaussabel D, et al. (2008) How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets. Immunol Rev 223: 39-59.
23. Engleman EG, Sonnenfeld G, Dauphinee M, Greenspan JS, Talal N, et al. (1981) Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum 24: 1396-1402.
24. Ronnblom LE, Alm GV, Oberg K (1991) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30: 537-540.
25. Kotzin BL (1996) Systemic lupus erythematosus. Cell 85: 303-306.
26. Andrews BS, Eisenberg RA, Theofilopoulos AN, Izui S, Wilson CB, et al. (1978) Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J Exp Med 148: 1198-1215.
27. Ohteki T, Seki S, Abo T, Kumagai K (1990) Liver is a possible site for the proliferation of abnormal CD3+4-8- double-negative lymphocytes in autoimmune MRL-lpr/lpr mice. J Exp Med 172: 7-12.
28. Reilly CM, Gilkeson GS (2002) Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res 25: 143-153.
29. Tsai TY, Choi YS, Ma W, Pomerening JR, Tang C, et al. (2008) Robust, tunable biological oscillations from interlinked positive and negative feedback loops. Science 321: 126-129.
30. Morse HC 3rd, Davidson WF, Yetter RA, Murphy ED, Roths JB, et al. (1982) Abnormalities induced by the mutant gene Ipr: expansion of a unique lymphocyte subset. J Immunol 129: 2612-2615.
31. Mandik-Nayak L, Seo SJ, Sokol C, Potts KM, Bui A, et al. (1999) MRL-lpr/ lpr mice exhibit a defect in maintaining developmental arrest and follicular exclusion of anti-double-stranded DNA B cells. J Exp Med 189: 1799-1814.
32. Krutzik PO, Clutter MR, Nolan GP (2005) Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry. J Immunol 175: 2357-2365.
33. Anderson SL, Carton JM, Lou J, Xing L, Rubin BY (1999) Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology 256: 8-14.
34. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, et al. (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367.
35. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924.
36. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921.
37. Ilangumaran S, Ramanathan S, Rottapel R (2004) Regulation of the immune system by SOCS family adaptor proteins. Semin Immunol 16: 351-365.
38. Ilangumaran S, Rottapel R (2003) Regulation of cytokine receptor signaling by SOCS1. Immunol Rev 192: 196-211.
39. Narazaki M, Fujimoto M, Matsumoto T, Morita Y, Saito H, et al. (1998) Three distinct domains of SSI-1/SOCS-1/JAB protein are required for its suppression of interleukin 6 signaling. Proc Natl Acad Sci U S A 95: 13130-13134.
40. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, et al. (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545.
41. Yu CR, Mahdi RM, Ebong S, Vistica BP, Chen J, et al. (2004) Cell proliferation and STAT6 pathways are negatively regulated in T cells by STAT1 and suppressors of cytokine signaling. J Immunol 173: 737-746.
42. Banchereau J, Pascual V (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
43. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, et al. (2000) Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664-671.
44. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, et al. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 18: 1309-1320.
45. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, et al. (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93: 385-395.
46. Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738.
47. Lehmann U, Schmitz J, Weissenbach M, Sobota RM, Hortner M, et al. (2003) SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J Biol Chem 278: 661-671.
48. Fischer P, Lehmann U, Sobota RM, Schmitz J, Niemand C, et al. (2004) The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J 378: 449-460.
49. Haring JS, Corbin GA, Harty JT (2005) Dynamic Regulation of IFN-{gamma} Signaling in Antigen-Specific CD8+ T Cells Responding to Infection. J Immunol 174: 6791-6802.
50. Petri M (1998) Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 24: 423-456.
51. Ingolia N (2005) Cell cycle: bistability is needed for robust cycling. Curr Biol 15: R961-963.